Bepreve

DRUG3 trials

Sponsors

Bausch & Lomb Incorporated, North Texas Institute for Clinical Trials

Conditions

Allergic ConjunctivitisConjunctivitis, AllergicHistamine Responsive Allergy Patients

Phase 2

Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis

CompletedNCT00424398

Bausch & Lomb IncorporatedConjunctivitis, Allergic

Start: 2007-02-28Updated: 2013-02-15

Phase 3

Safety Study for Bepotastine Besilate Ophthalmic Solution in Normal Volunteers

CompletedNCT00586625

Bausch & Lomb IncorporatedAllergic Conjunctivitis

Start: 2007-10-31Updated: 2013-02-15

Phase 4

The Evaluation of Bepreve on the Measurement of Wheal and Flare Response From Histamine Skin Prick Testing

CompletedNCT01128556

North Texas Institute for Clinical TrialsHistamine Responsive Allergy Patients

Start: 2010-04-30End: 2010-06-30Target: 30Updated: 2010-07-08

Related Papers

Integrated phase III trials of bepotastine besilate ophthalmic solution 1.5% for ocular itching associated with allergic conjunctivitis.

2012-05-016 citations

Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.

2009-09-0127 citations